Georg Evers1, Marcel Kamp2, Nils Warneke3, Wolfgang Berdel1, Michael Sabel2, Walter Stummer3, Christian Ewelt4. 1. Department of Medicine, Hematology and Oncology, University Hospital of Muenster, Muenster, Germany. 2. Department of Neurosurgery, University Hospital of Düsseldorf, Düsseldorf, Germany. 3. Department of Neurosurgery, University Hospital of Muenster, Muenster, Germany. 4. Department of Neurosurgery, University Hospital of Muenster, Muenster, Germany. Electronic address: christian.ewelt@ukmuenster.de.
Abstract
OBJECTIVE: Diagnosis of primary central nervous system lymphoma (PCNSL) is usually confirmed by brain biopsy and subsequent neuropathologic workup. 5-Aminolevulinic acid (5-ALA)-induced fluorescence has been established for diagnostic and therapeutic purposes in glioma treatment during the last few years and is discussed for use in other cranial tumors. Its role in diagnosis and treatment of PCNSL is still elusive. METHODS: This retrospective study includes clinical, magnetic resonance imaging, pathologic and surgical data of selected 11 patients with PCNSL at two university hospitals within the last 4 years undergoing surgical treatment for resection because of imminent mass effect or suspected cerebral glioma. Patients received 5-ALA for fluorescence-guided resection preoperatively. RESULTS: The 11 subjects age ranged from 59 to 81 years. Postsurgical pathologic workup revealed malignant B cell lymphoma with morphologic features of diffuse large B cell lymphoma. Eight of these 11 patients with PCNSL showed a clear fluorescence induced by 5-ALA. After surgical resection, patients were treated with combination chemotherapy regimens. CONCLUSION: In patients with glioma, the use of 5-ALA is known to be associated with increased extent of resection and survival benefit. Our data and retrospective analysis of a larger patient cohort suggest that the use of 5-ALA in PCNSL should be included in a surgical approach, if this is reconsidered for select patients within a clinical study. In addition, even photodynamic therapy in combination with 5-ALA might be studied.
OBJECTIVE: Diagnosis of primary central nervous system lymphoma (PCNSL) is usually confirmed by brain biopsy and subsequent neuropathologic workup. 5-Aminolevulinic acid (5-ALA)-induced fluorescence has been established for diagnostic and therapeutic purposes in glioma treatment during the last few years and is discussed for use in other cranial tumors. Its role in diagnosis and treatment of PCNSL is still elusive. METHODS: This retrospective study includes clinical, magnetic resonance imaging, pathologic and surgical data of selected 11 patients with PCNSL at two university hospitals within the last 4 years undergoing surgical treatment for resection because of imminent mass effect or suspected cerebral glioma. Patients received 5-ALA for fluorescence-guided resection preoperatively. RESULTS: The 11 subjects age ranged from 59 to 81 years. Postsurgical pathologic workup revealed malignant B cell lymphoma with morphologic features of diffuse large B cell lymphoma. Eight of these 11 patients with PCNSL showed a clear fluorescence induced by 5-ALA. After surgical resection, patients were treated with combination chemotherapy regimens. CONCLUSION: In patients with glioma, the use of 5-ALA is known to be associated with increased extent of resection and survival benefit. Our data and retrospective analysis of a larger patient cohort suggest that the use of 5-ALA in PCNSL should be included in a surgical approach, if this is reconsidered for select patients within a clinical study. In addition, even photodynamic therapy in combination with 5-ALA might be studied.
Keywords:
5-Aminolevolinic acid; Diffuse large B cell lymphoma; Fluorescence-guided surgery; Photodynamic therapy; Primary central nervous system lymphoma
Authors: Julia Steinmann; Marion Rapp; Bernd Turowski; Hans-Jakob Steiger; Jan Frederick Cornelius; Michael Sabel; Marcel A Kamp Journal: Neurosurg Rev Date: 2017-06-07 Impact factor: 3.042
Authors: Michael Sabel; Johannes Knipps; Lisa Margarete Neumann; Max Kieslich; Hans-Jakob Steiger; Marion Rapp; Marcel A Kamp Journal: Neurosurg Rev Date: 2018-07-23 Impact factor: 3.042
Authors: Johannes Knipps; Igor Fischer; Lisa M Neumann; Marion Rapp; Maxine Dibué-Adjei; Christiane Freiin von Saß; Jan-Malte Placke; Hendrik-Jan Mijderwijk; Hans-Jakob Steiger; Michael Sabel; Jan-Frederick Cornelius; Marcel A Kamp Journal: Clin Exp Metastasis Date: 2019-08-02 Impact factor: 5.150
Authors: Evgenii Belykh; Eric J Miller; Arpan A Patel; Baran Bozkurt; Kaan Yağmurlu; Timothy R Robinson; Peter Nakaji; Robert F Spetzler; Michael T Lawton; Leonard Y Nelson; Eric J Seibel; Mark C Preul Journal: Sci Rep Date: 2018-08-22 Impact factor: 4.379
Authors: Pierre Ferrer; Pablo Barbero; Gonzalo Monedero; Anna Lo Presti; Bartolome Bejarano; Juan Ramon Penanes Journal: Surg Neurol Int Date: 2020-05-23
Authors: Georgios Solomou; Aref-Ali Gharooni; Waqqas Patel; Conor S Gillespie; Melissa Gough; Ashwin Venkatesh; Michael T C Poon; Victoria Wykes; Stephen John Price; Michael D Jenkinson; Colin Watts; Puneet Plaha Journal: BMJ Open Date: 2022-07-22 Impact factor: 3.006
Authors: Alexander J Schupper; Manasa Rao; Nicki Mohammadi; Rebecca Baron; John Y K Lee; Francesco Acerbi; Constantinos G Hadjipanayis Journal: Front Neurol Date: 2021-06-16 Impact factor: 4.003